Filing identity and reporting period
The supplied filing is NanoAntibiotics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a BioVie Inc. filing or a 2013 Q3 filing as indicated in the request metadata. NanoAntibiotics was incorporated April 10, 2013 and describes itself as a development-stage biotechnology company.
Business context and key financial metrics
The company is developing efflux pump inhibitors and nanoantibiotics targeting drug-resistant bacteria. It had no products for sale and reported no revenue for the three or nine months ended March 31, 2014, or cumulatively since inception.
| Metric | Period/value |
|---|---|
| Operating expenses | $48,171 for the quarter; $149,036 for the nine months |
| Net loss | $48,041 for the quarter; $148,660 for the nine months; $166,170 since inception |
| Research and development | $49,419 for the nine months; quarterly amount is inconsistent within the filing |
| Cash and total current assets | $345,255 cash and $359,536 current assets at March 31, 2014 |
| Current liabilities | $2,500, consisting of accounts payable; no debt is reported on the balance sheet |
| Operating cash flow | $(160,441) used in the nine months ended March 31, 2014 |
| Financing cash flow | No financing cash flow in the nine-month period; $508,206 since inception |
| Shares outstanding | 87,210,000 at March 31, 2014 |
No meaningful prior-year comparable operating period is presented because the company began operations in April 2013. Interest income was $376 for the nine months. The filing reports no operating margin because there was no revenue.
Material changes and operating developments
Cash declined by $160,441 from June 30, 2013, while accounts payable decreased from $15,000 to $2,500. The company issued 150,000 shares for consulting services valued at $15,000. It reported preliminary in-vitro tracer-dye retention results in Staphylococcus epidermidis, but candidates had not been tested in animals and further work was needed before in-vivo studies.
Outlook, risks, and unusual items
Management estimated next-12-month costs of $650,000 for research and development, $100,000 for corporate overhead, $75,000 for capital costs, and $100,000 for staffing. It stated that approximately $600,000 of additional net financing was needed to meet its budget and that existing funds were insufficient for planned development. The filing also says existing cash was expected to cover operating and capital requirements until December 31, 2014; this statement should be considered alongside the stated funding shortfall.
The company had no committed financing and warned that failure to raise capital could force it to delay or reduce development, seek partners or licensing, or cease operations. The filing identifies substantial doubt about the company’s ability to continue as a going concern. Drug development, sourcing, regulatory approval, financing, and commercialization are significant uncertainties. Preliminary laboratory results are not evidence of clinical efficacy or regulatory approval.
A five-year office lease began January 1, 2014, with monthly payments of $357 and aggregate stated payments of $21,420. The company reported that disclosure controls and procedures were not effective as of March 31, 2014. It reported no material litigation and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer and period: the supplied document is NanoAntibiotics’ March 31, 2014 Form 10-Q, not BioVie’s 2013 Q3 filing.
- Resolve the research-and-development expense discrepancy: the statements show $19,409 for the quarter, while the notes state $2,659.
- Reconcile management’s runway statement through December 31, 2014 with its conclusion that current funds are insufficient and approximately $600,000 of additional financing is needed.
- Assess financing availability, going-concern risk, and the assumptions behind the development budget.
- Verify the status and reproducibility of the reported in-vitro findings and the timing, cost, and results of planned animal testing.